$ 273.60
Details
The RIK-2 monoclonal antibody specifically binds to CD253 which is also known as TRAIL (TNF-Related Apoptosis-Inducing Ligand) and Apo2 ligand (APO-2L). CD253 is a member of the Tumor Necrosis Factor Superfamily and is encoded by the TNFSF10 gene. CD253 is a type II membrane protein that may be expressed as a full-length, cell surface associated protein as well as in a soluble form. Both surface and soluble forms of TRAIL rapidly induce apoptosis by a wide range of cell lines but not by normal cells. TRAIL is expressed by activated T cells, NK cells, dendritic cells, monocytes and by a variety of non-lymphoid cells. TRAIL can bind to and exert apoptosis through DR4 (TRAIL-R1) and DR5 (TRAIL-R2) receptors. It can also bind to decoy receptors, including DcR1/TRID/TRAIL-R3 and DcR2/TRUNDD/TRAIL-R4, and possibly OPG/TNFRSF11B, which may serve to regulate TRAIL activity. TRAIL has been shown to be involved in T cell-mediated cytotoxicity, however its mechanism of action remains to be fully elucidated. The RIK-2 clone was selected based on its ability to block TRAIL-mediated cytotoxic activity.
